Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
复制标题
DOI：
10.1586/14760584.2.2.219
复制
发表时间：
2003-04-01
影响因子：
6.2
通讯作者：
Baldridge, Jory R
中科院分区：
文献类型：
--
作者：
Evans, Jay T;Cluff, Christopher W;Baldridge, Jory R
MPL（Corixa）佐剂是脂多糖的化学修饰衍生物，其显示出大大降低的毒性，同时保持脂多糖的大部分免疫刺激活性。MPL佐剂作为针对传染病、癌症和过敏的预防性和治疗性疫苗的组分已广泛用于临床试验。迄今为止，MPL佐剂已被施用超过33，000剂，已成为一种安全有效的疫苗佐剂。最近，Corixa Corporation的科学家开发了一个合成脂质A模拟物（氨基烷基氨基葡萄糖酰胺4-磷酸盐）库，具有已证实的免疫刺激特性。与MPL佐剂类似，这些合成化合物通过Toll样受体4发出信号以刺激先天免疫系统。其中一种化合物Ribi.529（RC-529）已成为一种领先的佐剂，在临床前和临床研究中具有与MPL佐剂相似的疗效和安全性。
MPL (Corixa) adjuvant is a chemically modified derivative of lipopolysaccharide that displays greatly reduced toxicity while maintaining most of the immunostimulatory activity of lipopolysaccharide. MPL adjuvant has been used extensively in clinical trials as a component in prophylactic and therapeutic vaccines targeting infectious disease, cancer and allergies. With over 33,000 doses administered to date, MPL adjuvant has emerged as a safe and effective vaccine adjuvant. Recently, scientists at Corixa Corporation have developed a library of synthetic lipid A mimetics (aminoalkyl glucosaminide 4-phosphates) with demonstrated immunostimulatory properties. Similar to MPL adjuvant, these synthetic compounds signal through Toll-like receptor 4 to stimulate the innate immune system. One of these compounds, Ribi.529 (RC-529), has emerged as a leading adjuvant with a similar efficacy and safety profile to MPL adjuvant in both preclinical and clinical studies.